Patient approach in advanced/metastatic renal cell carcinoma: Focus on the elderly population and treatment-related toxicity

Future Oncology

Volumn 9, Issue 11, 2013, Pages 1599-1607

  Verzoni, Elena ^a   De Braud, Filippo ^a   Fabiani, Francesca ^b   Grassi, Paolo ^a   Testa, Isabella ^a   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b San Giuseppe Hospital   (Italy)

Author keywords

elderly patient; metastatic renal cell carcinoma; sorafenib; sunitinib; targeted therapy; toxicity

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ANOREXIA; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BRAIN ISCHEMIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; ENDOCRINE DISEASE; EVIDENCE BASED PRACTICE; FATIGUE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY CANCER; KIDNEY METASTASIS; LIVER TOXICITY; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA; PAIN; PATIENT DECISION MAKING; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; REVIEW; SKIN MANIFESTATION; STOMATITIS; THYROID DISEASE; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LIVER; LUNG DISEASES;

EID: 84887309872     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.150     Document Type: Review

References (46)

1. Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J. Clin. Oncol. 28, 5017-5019 (2010).
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
3. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer. Inst. 100(20), 1454-1463 (2008).
4. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
5. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon a-2a in patients with metastatic renal cell carcinoma (AVOREN): fnal analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
6. Motzer RJ, Escudier B, Oudard S et al. Effcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
7. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
8. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011).
9. Verzoni E, Garanzini E, Procopio G. Complete responses in advanced renal cell carcinoma: utopia or real chance? Clin. Exp. Nephrol. 17(1), 151-152 (2013).
10. Motzer R, Hutson TE, Reeves J et al. Randomized, open label, Phase III trial of pazopanib versus sunitinib in frst-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial. Presented at: 37th ESMO Congress. Vienna, Austria, 28 September-2 October 2012.
11. Motzer R, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial. Presented at: 37th ESMO Congress. Vienna, Austria, 28 September-2 October 2012.
12. Bukowski RM, Stadler WM, McDermott DF et al. Safety and effcacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78, 340-347 (2010).
13. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
14. Procopio G, Bellmunt J, Dutcher J et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br. J. Cancer 108(2), 311-318 (2013).
15. Brunello A, Basso U, Sacco C et al. Safety and activity of sunitinib in elderly patients (>=70 years) with metastatic renal cell carcinoma: a multicenter study. Ann. Oncol. 24(2), 336-342 (2013).
16. Porta C, Calvo E, Climent MA et al. Effcacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur. Urol. 61, 826-833 (2012).
17. Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol. 59, 526-540 (2011).
18. Witteles RM, Telli M. Underestimating cardiac toxicity in cancer trials: lessons learned? J. Clin. Oncol. 30(16), 1916-1918 (2012).
19. Tolcher AW, Appleman LJ, Shapiro GI et al. A Phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 67(4), 751-764 (2011).
20. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. N. Engl. J. Med. 365(17), 1649-1650 (2011).
21. Verma N, Swain SM. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J. Clin. Oncol. 29(6), 603-606 (2011).
22. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28(13), 2280-2285 (2010).
23. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300, 2277-2285 (2008).
24. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta. Oncol. 49, 287-297 (2010).
25. Qi WX, Min DL, Shen Z et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int. J. Cancer 132(12), 2967-2974 (2012).
26. Rini BI. Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. Clin. Adv. Hematol. Oncol. 9(4), 337-338 (2011).
27. Shinohara N, Takahashi M, Kamishima T et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br. J. Cancer 104(2), 241-247 (2011).
28. Daimon M, Kato T, Kaino W et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J. Clin. Oncol. 42(8), 742-747 (2012).
29. Habib SL, Prihoda TJ, Luna M, Werner SA. Diabetes and risk of renal cell carcinoma. J. Cancer 3, 42-48 (2012).
30. Houde VP, Brule S, Festuccia WT et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59(6), 1338-1348(2010).
31. Oh JJ, Hong SK, Joo YM et al. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J. Clin. Oncol. 42(4), 314-317 (2012).
32. Bohm S, Hess D, Gillessen S, Brandle M et al. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diabetes Care 33(6), e82 (2010).
33. Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Future Oncol. 8(8), 1051-1057 (2012).
34. Magremanne M, Lahon M, De Ceulaer J, Reychler H. Unusual bevacizumab-related complication of an oral infection. J. Oral. Maxillofac. Surg. 71(1), 53-55 (2013).
35. Visvardis EE, Gao F, Paes MN, Duprez O, Waxman J. Lung aspergillosis in renal cell carcinoma patient treated with sunitinib. Q JM 105(7), 689-692 (2012).
36. Myung HJ, Jeong SH, Kim JW et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver 4(4), 543-546 (2010).
37. Koga M, Nakayama I, Sakai T, Koga K, Imafuku S, Nakayama J. Disseminated herpes simplex virus type-1 infection in long-term usage of everolimus. J. Dermatol. 40(1), 83-84 (2013).
38. Gotze KS, Hoffmann D, Schatzl HM, Peschel C, Fend F, Decker T. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Haematologica 92(9), 1282-1283(2007).
39. Fijalkowska-Morawska JB, Jagodzinska M, Nowicki M. Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. Ann. Transplant. 16 (4), 107-110 (2011).
40. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic fndings and correlation with clinical outcome. Eur. J. Cancer 48 (10), 1519-1524 (2012).
41. Klempner SJ, Choueiri TK, Yee E, Doyle LA, Shuppan D, Atkins MB. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J. Clin. Oncol. 30, 264-268 (2012).
42. Goh BC, Reddy NJ, Dandamudi UB et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modifed Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin. Pharmacol. Ther. 88, 652-659 (2010).
43. Xu CF, Xue Z, Bing N et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann. Oncol. 23(9), 2470-2471 (2012).
44. Launay-Vacher V, Ayllon J, Janus N et al. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol. Oncol. 29(5), 492-494 (2011).
45. Khan G, Golshayan A, Elson P et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insuffciency. Ann. Oncol. 21(8), 1618-1622 (2010).
46. Masini C, Sabbatini R, Porta C et al. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 110(5), 692-698 (2012).